FDA approve cemiplimab for use in advanced basal cell carcinoma

The specific approval, is for previously-treated, advanced basal cell carcinoma in patients who have already received a hedgehog pathway inhibitor (HHI). It was found to provide an overall response rate of 21% and 29% in metastatic and locally advanced cancer respectively.

PharmaTimes